Uganda & Moderna

Uganda: Uganda has confirmed cases of Ebola linked to the outbreak in the Democratic Republic of the Congo, leading to border closures and quarantine measures. Its authorities have expressed unawareness of US-funded treatment centers.

Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.

Uganda: Uganda has confirmed imported Ebola cases from the Democratic Republic of the Congo, leading to heightened surveillance, travel restrictions, and the postponement of national events to prevent further spread.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Uganda: Uganda>>> has reported confirmed Ebola cases linked to the outbreak in the Democratic Republic of the Congo>>>, leading to border closures and heightened surveillance efforts, while also expressing concern over the Uganda — Bundibugyo virus being named after one of its districts.

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.

Uganda: Uganda has confirmed nine cases of Ebola Bundibugyo, including one death, indicating the regional spread of the outbreak.

Moderna: Moderna received up to $50 million from CEPI to support the preclinical and early clinical development of its mRNA-based Ebola Bundibugyo vaccine candidate, leveraging its mRNA platform for rapid response.

Uganda: Neighboring country that experienced cases and deaths, declared free of the virus last month. At risk of renewed spread, impacting its health system and economy.

Moderna: Authorized to begin Phase 1 trials for a Bundibugyo vaccine, using mRNA technology. Potential for significant revenue if successful.

Uganda: Neighboring country that contained its linked outbreak, declaring itself Ebola-free. Its success provides a model for containment but remains at risk of cross-border spread.

Moderna: Developed an mRNA-based Bundibugyo vaccine candidate, with Phase 1 trials starting in Canada. Its mRNA platform could offer a rapid response to emerging outbreaks.

Uganda: Uganda is experiencing outbreaks of Ebola Disease, leading to a Public Health Emergency of International Concern and a suspected case in India originating from there.

Moderna: Moderna is one of the groups receiving funding to develop an Ebola vaccine, indicating potential future market opportunities.